Insider · CIK 0002075371
Elizabeth C. Cushman
officer
Files at ABT (ABBOTT LABORATORIES). First filing Mar 3, 2026, latest Mar 3, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $30k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABT: ABBOTT LABORATORIES
ABTOct 9, 2026 · close 99.60
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | ABBOTT LABORATORIES | $30k 263 shares | -1% | +8% from low-17% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | ABT ABBOTT LABORATORIES | FTax withholding Common shares without par value | -1,421 | $116.26 | $165k | 38,836 | Mar 3, 2026 |
| Mar 2, 2026 | ABT ABBOTT LABORATORIES | SOpen-market sale Common shares without par value | -263 | $115.58 | $30k | 38,573 | Mar 3, 2026 |
| Feb 24, 2026 | ABT ABBOTT LABORATORIES | AGrant or award Common shares without par value | +15,031 | $0.00 | $0 | 40,257 | Feb 26, 2026 |
| Feb 24, 2026 | ABT ABBOTT LABORATORIES | AGrant or award Option (right to buy)derivative | +61,964 | $0.00 | $0 | 61,964 | Feb 26, 2026 |
| Jun 27, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Common shares without par value | +3,790 | $0.00 | $0 | 25,226 | Jul 1, 2025 |
| Jun 27, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Option (right to buy)derivative | +14,680 | $0.00 | $0 | 14,680 | Jul 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.